Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for
patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will
be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus
ado-trastuzumab emtansine phase II arm will be for patients with HER2 overexpressing MBC.
There will be two phase II cohorts for pembro plus cetuximab: one cohort will be for patients
with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype
metastatic CRC.